Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

The prognosis of relapsed B cell precursor acute lymphoblastic leukemia (B‐ALL) is poor and few patients can be successfully rescued with conventional therapies. Inotuzumab ozogamicin (IO), an antibody against the CD22 antigen linked to calicheamicin, has been approved as a rescue treatment in relapsed/refractory (R/R) B‐ALL.

[1]  A. Logan,et al.  Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia , 2023, American journal of hematology.

[2]  R. Schlenk,et al.  Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin , 2022, Haematologica.

[3]  M. Konopleva,et al.  A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia , 2021, Blood.

[4]  M. Liedtke,et al.  Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia , 2020, Cancer.

[5]  M. Liedtke,et al.  Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden , 2020, Blood Cancer Journal.

[6]  H. Kantarjian,et al.  Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database , 2020, Leukemia & lymphoma.

[7]  M. Liedtke,et al.  Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. , 2020, Clinical lymphoma, myeloma & leukemia.

[8]  M. Liedtke,et al.  Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. , 2019, Leukemia research.

[9]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis , 2019, Cancer.

[10]  M. Liedtke,et al.  Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study , 2019, Cancer.

[11]  S. Paolini,et al.  Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia , 2018, BMC Cancer.

[12]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[13]  W. Klapper,et al.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.

[14]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[15]  H. Gerber,et al.  Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. , 2015, Molecular immunology.

[16]  K. Kreuzer,et al.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.

[17]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet. Oncology.

[18]  M. Tormo,et al.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.

[19]  H. Kantarjian,et al.  Outcome of adults with acute lymphocytic leukemia after second salvage therapy , 2008, Cancer.

[20]  H. Dombret,et al.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.